Infinite Load Articles

CIRM approves $6 million in funding for UCI Researchers to study...

Following a California Institute for Regenerative Medicine (CIRM) Independent Citizens Oversight Committee meeting held last week, University of California, Irvine (UCI) researchers learned they...

ALBORADA Drug Discovery Institute identifies advanced Huntington’s leads using BioAscent’s Compound...

BioAscent’s unique on-demand compound library, Compound Cloud, has been used by the ALBORADA Drug Discovery Institute for virtual screening and to progress promising leads against a novel Huntington’s...

Expert-based clinical guidelines focus on behavioral symptoms in Huntington’s disease

Clinicians treating patients with HD are often not trained to recognize or treat neuropsychiatric symptoms of the disease, according to new guidelines published in...

Huntington’s disease goes viral as UniQure inches ahead in gene therapy...

FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients Dutch-American company uniQure has received...

First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for...

First of 4+ Ionis programs expected to advance to pivotal studies this yearIonis earns $35 million milestone payment CARLSBAD, Calif., Jan. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130...

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients...

LATEST ARTICLES

Print Friendly, PDF & Email
0 Condivisioni